• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Humacyte, JDRF to develop biovascular pancreas to treat type 1 diabetes

April 27, 2023 By Sean Whooley

JDRF HumacyteHumacyte (Nasdaq:HUMA) and JDRF announced today that they entered into a collaboration to develop a biovascular pancreas (BVP).

The collaboration aims to advance the development of Humacyte’s BVP product candidate for treating type 1 diabetes. Humacyte designed its BVP to deliver insulin-producing islets using its investigational, tissue-engineered blood vessel. The company calls it the Human Acellular Vessel (HAV).

Under the agreement, JDRF plans to provide Humacyte with funding to support the development and testing of the BVP.

“We are proud to be collaborating with JDRF, one of the leading organizations in the world focused on T1D research,” said Dr. Laura ​​Niklason, founder and CEO of Humacyte. “Humacyte’s HAV technology, combined with insulin-producing islets, may constitute a groundbreaking development in the treatment of T1D in the future.

“Successful development of the BVP could improve the lives of millions of patients, and their families, who are suffering with this chronic and debilitating disease.”

Humacyte said the BVP could enable the delivery and survival of insulin-producing islets inside the body. The company’s bioengineered HAV acts as a “carrier” for the delivery of the islets. This technology could overcome many of the hurdles currently associated with implanting islets in diabetic patients, Humacyte said.

If successful, the platform could increase the effectiveness of treating type 1 diabetes patients with islet cells.

“JDRF is committed to supporting the development of cell replacement therapies that could one day offer cures for type 1 diabetes,” said Esther Latres, JDRF VP of research. “Through the successful replacement of lost or damaged insulin-producing cells, Humacyte’s Biovascular Pancreas has the potential to solve roadblocks in the delivery of insulin-producing cells, and change the lives of those living with the disease.

“We’re excited to support the ongoing development of this technology.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Research & Development Tagged With: Humacyte, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS